Immunocidin Mycobacterium Cell Wall Fraction Immunostimulant

Supplied By: Vedco (VINV-FR11-4800)


SKU
057023


Unit of
Measure
2.5mL


Pack
Type
Vial


Case
Qty
1

{{promo.PromoName}}

{{promo.PromoText}}

{{promo.StartDate | date : 'MM/dd/yyyy'}} - {{promo.EndDate | date : 'MM/dd/yyyy'}}

Jul- 2020 Jun- 2020 May- 2020 Apr- 2020 Mar- 2020 Feb- 2020 Jan- 2020 Dec- 2019 Nov- 2019 Oct- 2019 Sep- 2019 Aug- 2019 Jul- 2019
{{purchaseHistoryItem}}


SKU
057023


Size
2.5mL

Case
Qty
1

Purchase History

Jul- 2020 {{productPurchaseHistory['057023'][0]}} Dec- 2019 {{productPurchaseHistory['057023'][0+7]}}
Jun- 2020 {{productPurchaseHistory['057023'][1]}} Nov- 2019 {{productPurchaseHistory['057023'][1+7]}}
May- 2020 {{productPurchaseHistory['057023'][2]}} Oct- 2019 {{productPurchaseHistory['057023'][2+7]}}
Apr- 2020 {{productPurchaseHistory['057023'][3]}} Sep- 2019 {{productPurchaseHistory['057023'][3+7]}}
Mar- 2020 {{productPurchaseHistory['057023'][4]}} Aug- 2019 {{productPurchaseHistory['057023'][4+7]}}
Feb- 2020 {{productPurchaseHistory['057023'][5]}} Jul- 2019 {{productPurchaseHistory['057023'][5+7]}}
Jan- 2020 {{productPurchaseHistory['057023'][6]}}
{{promo.PromoName }}

{{promo.PromoText}}

{{promo.StartDate | date : 'MM/dd/yyyy'}} - {{promo.EndDate | date : 'MM/dd/yyyy'}}

Compare Products

{{compareProd.sku}}
{{compareProd.desc}}

{{compareMessage}}

Product Description

lmmunocidin is a veterinary biologic for the treatment of mammary cancer in dogs and horses. It's based on the company's mycobacterial cell wall (MCW) technology platform, derived from M. phlei.

The efficacy of lmmunocidin and related MCW-based products is due to their novel immunological activity. Mycobacteria have been known for many years to have antitumor activity. lmmunocidin TM is an emulsion of mycobacterial cell wall fractions which have been modified to reduce their toxic and allergic effect but retain their antitumor activity. lmmunocidin stimulates the activation of macrophages and T-lymphocytes which destroy tumor cells. Although lmmunocidin is administered by intratumoral injection, the response is generalized, and untreated sites frequently undergo regression.